Japan Anti Neprilysin Drugs Market Insight
Published: 04 June 2026 | Report Format: Electronic (PDF)
The Japan anti neprilysin drugs market is expected to grow at a CAGR of 7.34%, driven by rising heart failure cases, an aging population, expanding ARNI therapy adoption, broader regulatory approvals, and cardiovascular drug innovation.
Japan Anti Neprilysin Drugs Market Insights Forecasts to 2035
- The Japan Anti Neprilysin Drugs Market Size Was Estimated USD 412.8 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.34% from 2025 to 2035
- The Japan Anti Neprilysin Drugs Market Size is Expected to rise around USD 841.6 Million by 2035
Notable Insights for the Japan Anti Neprilysin Drugs Market
- Based on the Segmentation by Drug Type, it can be observed that the Small-Molecule ARNI Inhibitors & Sacubitril/Valsartan Combination Therapies segment is taking lead in the Japan Anti Neprilysin Drugs Market in 2025, holding almost 76% of the total market share due to the widespread clinical adoption of Entresto® (sacubitril/valsartan) across chronic heart failure, hypertension, and newly approved pediatric heart failure indications in Japan, supported by strong guideline endorsement from the Japanese Circulation Society.
- Based on the Segmentation by Indication, it can be seen that the Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) segment held a market share of about 68% in the Japan Anti Neprilysin Drugs Market in 2025, mainly driven by Japan’s rapidly aging demographic, high national prevalence of hypertensive heart disease, and increasing physician adoption of ARNI therapy following updated Japanese Circulation Society and ESC heart failure guidelines positioning sacubitril/valsartan as a first-line treatment standard.
- Novartis AG, the global market leader in anti-neprilysin therapies through its flagship Entresto® (sacubitril/valsartan) product, reported full-year Entresto revenues of approximately USD 7.75 Billion globally for fiscal year 2025, with robust demand-led growth in Japan driven by increasing penetration in both heart failure and hypertension indications, co-promoted by Novartis Pharma K.K. and Otsuka Pharmaceutical Co., Ltd. under their long-standing Japan co-promotion agreement.
- It is expected that Japan’s government-backed cardiovascular disease prevention programs, increasing ARNI prescribing across outpatient cardiology centers, and expansion of sacubitril/valsartan into pediatric and preserved ejection fraction indications will drive market growth, where advanced ARNI therapies reduce cardiovascular death and heart failure hospitalization by up to 20% and lower systolic blood pressure in hypertensive patients by up to 15 mmHg versus conventional ARB therapy in Japanese clinical studies.
Download the eBook (ToC)
What Makes Decisions Advisors Research Unique?
- Intelligent Market Research Based on AI for Healthcare
Decisions Advisors offers intelligent market research which includes advanced analysis of anti-neprilysin drug mechanisms, ARNI clinical pipeline developments, cardiovascular drug regulatory approval pathways in Japan, and guideline-directed medical therapy adoption trends across Japan’s cardiology and hypertension treatment landscape. Our research identifies potential areas of business development, technology adoption rates, competitive position analysis, and important strategic changes in the Japan Anti Neprilysin Drugs Market.
- Highly Effective Research Approaches with Accurate Forecast Analysis
The research process uses advanced methodologies such as primary research interview approaches, clinical literature review, tracking the anti-neprilysin drug value chain from pipeline development to commercial dispensing, and data triangulation to deliver accurate market sizing, CAGR forecasting, investment analysis, and clinical adoption forecasting. The study examines the demand for anti-neprilysin therapies across heart failure, hypertension, pediatric cardiology, and preserved ejection fraction applications in Japan’s hospital, outpatient, and community pharmacy channels.
- Highly Competitive Environment Analysis
In-depth analysis of key anti-neprilysin drug developers, ARNI clinical trial outcomes, new indication approvals, co-promotion partnership activities, and generic entry risk assessments is included in the report. The report also covers Japan’s MHLW drug approval policies, Japanese Circulation Society prescribing guideline updates, national drug reimbursement pricing under Japan’s National Health Insurance system, and new competitive opportunities available in the Japan Anti Neprilysin Drugs Market.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Japan Anti Neprilysin Drugs Market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in Japan Anti Neprilysin Drugs Market
- Novartis Pharma K.K.
- Otsuka Pharmaceutical Co., Ltd.
- Daiichi Sankyo Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Astellas Pharma Inc.
- Pfizer Japan Inc.
- Merck & Co., Inc. (MSD Japan)
- AstraZeneca K.K.
- Boehringer Ingelheim Japan Inc.
- Bristol-Myers Squibb K.K.
Recent Developments:
- In March 2024, Novartis Pharma K.K. received approval for pediatric Entresto granular tablets, expanding anti-neprilysin therapy options for children with chronic heart failure in Japan.
- In February 2024, Novartis Pharma K.K. and Otsuka Pharmaceutical Co., Ltd. gained approval for pediatric use of Entresto, expanding ARNI therapy for chronic heart failure in Japan.
Market Segmentation:
Japan Anti Neprilysin Drugs Market, By Drug Type
- Small-Molecule ARNI Inhibitors (Sacubitril/Valsartan)
- Standalone Neprilysin Inhibitor Therapies
- Biologic Antibody-Based Neprilysin Inhibitors
- Next-Generation Combination ARNI Platforms
- Pediatric Anti Neprilysin Formulations
Japan Anti Neprilysin Drugs Market, By Indication
- Chronic Heart Failure with Reduced Ejection Fraction (HFrEF)
- Heart Failure with Preserved Ejection Fraction (HFpEF)
- Hypertension & Resistant Hypertension
- Pediatric Chronic Heart Failure
- Chronic Kidney Disease & Cardiorenal Syndrome
Japan Anti Neprilysin Drugs Market, By Distribution Channel
- Hospital Pharmacies & Cardiology Centers
- Retail & Community Pharmacies
- Online & E-Pharmacy Channels
- Government & National Health Insurance Dispensing
- Outpatient Specialty Cardiology Clinics
Expert Views:
The Japan Anti Neprilysin Drugs Market will experience growth owing to the growing adoption of ARNI therapy as guideline-directed first-line treatment for heart failure, Japan’s aging population driving sustained cardiovascular disease burden, and the expansion of sacubitril/valsartan into pediatric and hypertension indications under MHLW approvals. The integration of next-generation biologic neprilysin inhibitor platforms, expanded clinical indications for HFpEF and cardiorenal syndrome, and continued co-promotion collaboration between Novartis Pharma K.K. and Otsuka Pharmaceutical will drive sustained demand for anti-neprilysin therapies across Japan’s cardiovascular drug market through 2035.
Author: Komal and Radhika By Spherical Insights and Consulting